Implications for medical genetics of the House of Commons Science and Technology Committee's report on human genetics
The House of Commons Science and Technology Committee's report' follows consultation in Britain and in the USA with an impressive list of those giving evidence and a very wide scope, from genetics in the Health Service to ethical issues thrown up by the Human Genome Programme. The importance of genetic education of the population, schools, medical schools, and professions is stressed and the report calls for a Human Genetics Commission to be established by Act of Parliament to oversee the whole subject.
Cynics will claim that we have had enough exhortations2 and reports on genetics services in Britain3"-and now we need adequate funding and implementation. However, unprecedented molecular genetics developments coupled with raised public expectations have to be accommodated within an NHS subjected to radical change. An internal market in health care, the purchaserprovider split, and the demise of the old regional health authorities, all threaten regional services. Although groupings of health districts with lead purchasers have in some places been established to allow funding strategies based on a decent sized population base, the latest initiative from the NHS Executive encourages the devolution of priority setting for genetics to fund holding GPs. Few GPs would have list sizes big enough to allow rational planning of services for genetic disorders, most of which are too rare to allow a GP to have had meaningful experience of them. The situation is further complicated by important changes, to be implemented by 1998, in the method offunding NHS research and development following the Culyer report.22
Will these NHS reforms damage the ability of genetics services and research to match clinical and population needs? In the increasingly commercial environment of British health care will purchasers demand inappropriate outcome measures and will hard pressed medical geneticists be expected to deal with large scale genetic screening for susceptibility to common disease, or will other hospital specialities demand and receive development funds to duplicate existing genetic services? Who will regulate access by employers and insurance companies to genetic screening results and what are the implications of the spread of private laboratories and unregulated commercial patenting of human genes? Who will undertake the massive task of educating professionals and population?
These questions and others have been addressed in the Science and Technology Committee's report which, as noted earlier, calls for a Human Genetics Commission with statutory powers to implement its decisions. Specific recommendations include the need for monitoring the effects of NHS reforms on R&D and on patients' access with monitoring of the quality of genetics services. The report recommends caution in adopting outcome measures for genetics services, recognising that many beneficial outcomes depend upon hard to measure results of accurate and empathic counselling which enable people to make autonomous decisions: the quality of genetics cannot be measured by counting abortions. The report notes that it is premature to devolve funding of services to the GP level, although more emphasis should be given to the partnership between genetic centres and primary care and the need to provide training and resources for these purposes.
Much formation that is sufficiently precise to enable them to make informed decisions on the interventions available". Not really the dramatic progress that some had hoped for but at least another step in the long process of building genetics services. How medical genetics actually evolves is inevitably linked with current realities and how health care systems are regarded by different political ideologies. But medical geneticists must collaborate with primary care and others to contribute to health services at the millenium.
